0.875

7.89% -0.075

Neurosense Therapeutics Ltd (NRSN)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$0.95

Offen:

$0.97

24-Stunden-Volumen:

1.20M

Relative Volume:

1.95

Marktkapitalisierung:

$25.99M

Einnahmen:

Nettoeinkommen (Verlust:

$-10.21M

KGV:

-1.4978

EPS:

-0.5842

Netto-Cashflow:

1W Leistung:

-28.86%

1M Leistung:

-7.41%

6M Leistung:

-58.92%

1J Leistung:

-14.22%

1-Tages-Spanne:

$0.86

$0.97

1-Wochen-Bereich:

$0.86

$1.24

52-Wochen-Spanne:

$0.81

$2.60

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Firmenname

Neurosense Therapeutics Ltd

Sektor

Healthcare (1124)

Branche

Biotechnology (627)

Telefon

Adresse

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-11-26

Neueste SEC-Einreichungen

NRSN's Discussions on Twitter

Vergleichen Sie NRSN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NRSN Neurosense Therapeutics Ltd	0.875	28.21M	0	-10.21M	0	-0.5842
VRTX Vertex Pharmaceuticals Inc	444.64	110.88B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	726.21	72.79B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	890.11	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	404.46	54.85B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	189.85	41.41B	447.02M	-1.18B	-906.14M	-6.1812

Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten

Dec 09, 2025

Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance

Dec 09, 2025

A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) - Setenews

Dec 09, 2025

Dec 08, 2025

NRSN: PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope - TradingView

Dec 08, 2025

NRSN: Global phase III ALS trial set for mid-2026, with strong efficacy and active partnership talks - TradingView

Dec 08, 2025

NeuroSense Completes Data Collection for Alzheimer’s Trial - TipRanks

Dec 08, 2025

NeuroSense (NRSN) locks RoAD Phase 2 Alzheimer’s trial database, eyes Q1 2026 data - Stock Titan

Dec 08, 2025

NeuroSense completes data collection for Alzheimer’s trial - MSN

Dec 08, 2025

Dec 05, 2025

Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser

Dec 05, 2025

How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser

Dec 05, 2025

Dec 04, 2025

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq

Dec 04, 2025

NeuroSense Therapeutics LtdResuming regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis - marketscreener.com

Dec 04, 2025

NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks

Dec 04, 2025

Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView

Dec 04, 2025

NeuroSense (NASDAQ: NRSN) plans April 2026 Health Canada pre-NDS as it eyes mid-2026 NDS - Stock Titan

Dec 04, 2025

Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser

Dec 04, 2025

How interest rate cuts could boost NeuroSense Therapeutics Ltd. Equity Warrant stockWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser

Dec 04, 2025

Dec 03, 2025

NeuroSense Therapeutics (NRSN) Stock Analysis Report | Financials & Insights - Benzinga

Dec 03, 2025

Dec 02, 2025

What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockPortfolio Value Summary & Risk Managed Investment Signals - Newser

Dec 02, 2025

Dec 01, 2025

Aug EndMonth: How NeuroSense Therapeutics Ltd stock compares to growth peersWeekly Investment Report & Risk Managed Investment Strategies - BỘ NỘI VỤ

Dec 01, 2025

Nov 29, 2025

Is NeuroSense Therapeutics Ltd H1Z a good long term investmentMean Reversion Trades & High Return Capital Strategies - earlytimes.in

Nov 29, 2025

Nov 28, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) - Aktiellt

Nov 28, 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire) - Aktiellt

Nov 28, 2025

Nov 27, 2025

Hedge Fund Moves: How NeuroSense Therapeutics Ltd. stock compares to growth peers2025 Bull vs Bear & Proven Capital Preservation Methods - moha.gov.vn

Nov 27, 2025

Nov 25, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Given “Buy” Rating at D. Boral Capital - Defense World

Nov 25, 2025

NeuroSense Gains FDA Approval for Phase 3 ALS Trial - MSN

Nov 25, 2025

Prepare Yourself for Liftoff: NeuroSense Therapeutics Ltd (NRSN) - Setenews

Nov 25, 2025

Nov 24, 2025

D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq

Nov 24, 2025

NeuroSense receives FDA clearance to initiate pivotal phase 3 trial for PrimeC in ALS - marketscreener.com

Nov 24, 2025

NeuroSense Therapeutics (NRSN) Maintains 'Buy' Rating and $14 Ta - GuruFocus

Nov 24, 2025

NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS - marketscreener.com

Nov 24, 2025

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - Barchart.com

Nov 24, 2025

NeuroSense (Nasdaq: NRSN) to start pivotal Phase 3 PARAGON trial of PrimeC in ALS - Stock Titan

Nov 24, 2025

Nov 21, 2025